Cargando…

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia

The prognostic significance of bone marrow minimal residual disease (MRD) in pediatric patients with acute myeloid leukemia (AML) is well characterized, but the impact of blood MRD is not known. We, therefore, used flow cytometric assessment of leukemia-specific immunophenotypes to measure levels of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karol, Seth E., Coustan-Smith, Elaine, Pounds, Stanley, Wang, Lei, Inaba, Hiroto, Ribeiro, Raul C., Pui, Ching-Hon, Klco, Jeffery M., Rubnitz, Jeffrey E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365945/ https://www.ncbi.nlm.nih.gov/pubmed/37058475 http://dx.doi.org/10.1182/bloodadvances.2022009534

Ejemplares similares

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy
por: Pui, Ching-Hon, et al.
Publicado: (2016)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

A 6-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia
por: Elsayed, Abdelrahman H., et al.
Publicado: (2019)

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
por: Nguyen, Rosa, et al.
Publicado: (2019)

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
por: Raghuram, Nikhil, et al.
Publicado: (2023)

Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones
por: Osman, Afaf E. G., et al.
Publicado: (2022)

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia
por: Marrero, Richard J., et al.
Publicado: (2023)

Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
por: Rubnitz, Jeffrey E., et al.
Publicado: (2009)

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
por: Martínez-Cuadrón, David, et al.
Publicado: (2022)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
por: Pavlovsky, Carolina, et al.
Publicado: (2021)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
por: Lambert, Juliette, et al.
Publicado: (2021)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
por: Courjon, Johan, et al.
Publicado: (2021)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16
por: Gruber, Tanja A., et al.
Publicado: (2022)

Minimal residual disease in pediatric ALL
por: Pui, Ching-Hon, et al.
Publicado: (2017)

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
por: Chihara, Dai, et al.
Publicado: (2021)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
por: Fox, Christopher P., et al.
Publicado: (2021)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosis
por: Umeda, Masayuki, et al.
Publicado: (2023)

Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
por: Hamilton, Betty K., et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
por: Ekberg, Sara, et al.
Publicado: (2022)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Circulating SARS-CoV-2(+) megakaryocytes are associated with severe viral infection in COVID-19
por: Fortmann, Seth D., et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials
por: Valtis, Yannis K., et al.
Publicado: (2021)

Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis
por: Ataga, Kenneth I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_la3c74g2e5cpj3ea3uana2lrf3